HERAN Partners
HERAN Partners is a Belgium-based specialist venture capital firm founded in 2020 that invests at seed to Series B in European medtech and healthtech companies with two funds totalling over €165 million in assets under management.
- Company typePrivate
- Founded2020
- HeadquartersAntwerp, Belgium
- Headcount1–10
- GTM typeB2B
- OfferingServices
What HERAN Partners does
HERAN Partners is a Belgium-based specialist venture capital firm founded in 2020 that invests in early-stage medtech and healthtech companies across Europe. The firm deploys capital through two vehicles: HERAN HealthTech Fund I (€75.5 million closed, fully deployed across 15 companies in Belgium, the Netherlands and the UK with over 30% reported IRR and four exits) and HERAN HealthTech Fund II (€90 million closed, targeting €110-120 million, with first investments into Pharmacelera and Fluidic Sciences). HERAN targets seed, Series A and Series B opportunities in enabling technologies — including AI-assisted medical imaging, quantum-mechanics-based drug discovery, hyperspectral imaging, spatial omics, and clinical workflow optimisation — with B2B commercialisation pathways and a strong clinical backbone.
The firm operates without proprietary technology products; its core offering combines capital with active engagement, mentorship, board participation, and a network spanning academic institutes (notably KU Leuven Research & Development), corporates, and other venture investors. Distribution and deal sourcing run through a pitch submission portal, the Innovate UK Investor Partnerships Programme, an annual Investor Day, and direct outreach by an 11-person team based in Antwerp. Strategic investors in Fund II include the European Investment Fund (€20M cornerstone), PMV (€10M, doubled from Fund I), BNP Paribas Fortis, Finance&Invest Brussels, KU Leuven Research & Development, and a cohort of entrepreneurs and portfolio-company founders.
HERAN's revenue model is conventional asset management economics: a percentage-based management fee on committed or invested capital across both funds, plus carried interest on profitable exits. Fund I's exits (Bluebee to Illumina, PharmaFluidics to Thermo Fisher Scientific, UgenTec to Summa Equity, icometrix to GE Healthcare) demonstrate that the firm's primary "customers" — limited partners and portfolio companies — are served through capital allocation plus hands-on operational support rather than product sales, and Fund II is structured under SFDR Article 8 with ESG due diligence across the investment lifecycle.
HERAN Partners firmographics
Firmographics- Name
- HERAN Partners
- Legal name
- HERAN Partners
- Website
- https://heranpartners.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- HERAN Partners is a Belgium-based specialist venture capital firm founded in 2020 that invests at seed to Series B in European medtech and healthtech companies with two funds totalling over €165 million in assets under management.
- Ownership category
- akta.pro rank
Where HERAN Partners is headquartered
LocationHeadquarters
- HQ city
- Antwerp
- HQ country
- Belgium
- HQ region
- Europe
Offices1 record
Markets served
HERAN Partners business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Others
Revenue model
- Venture Capital Fund Management: HERAN generates returns through management fees and carried interest from fund investments. Fund I (HERAN HealthTech Fund I) closed at €75.5 million and invested in 15 companies across Belgium, the Netherlands and the UK, achieving an IRR of over 30% with four successful exits (Bluebee, PharmaFluidics, UgenTec, and icometrix). Fund II (HERAN HealthTech Fund II) has raised €90 million closing with a target of €110-120 million.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
HERAN Partners product offering
Product offeringCore offering
HERAN Partners is a specialist venture capital firm that invests venture and growth capital in early-stage healthcare, medtech, and life sciences companies across Europe. The firm manages dedicated HealthTech funds that deploy capital at seed, Series A and Series B stages into enabling technologies with strong clinical backbones and B2B commercialization strategies, complemented by mentorship, network access and operational support to portfolio companies.
Product overview
HERAN Partners is a specialist venture capital firm that provides investment products rather than traditional technology products. The firm operates two main investment vehicles: HERAN HealthTech Fund I (€75.5 million) and HERAN HealthTech Fund II (currently €90 million, targeting €110-120 million). These funds invest in early-stage medtech and healthtech companies across Europe, focusing on enabling technologies in healthcare and life sciences. The firm also offers mentorship, hands-on support, and operational expertise to portfolio companies as part of its investment approach.
Differentiator
Problem solved
Functional benefit
Products and services
- HERAN HealthTech Fund I HERAN's first venture capital fund (€75.5M) targeting early-stage medtech and healthtech companies in Europe. Invested in 15 companies across Belgium, the Netherlands, and the UK, achieving over 30% IRR with four successful exits (Bluebee acquired by Illumina, PharmaFluidics by Thermo Fisher, UgenTec by Summa Equity, icometrix by GE Healthcare).
- HERAN HealthTech Fund II HERAN's second venture capital fund (€90M closing, targeting €110-120M) investing in early-stage medtech and healthtech companies across Europe. First investments made in Pharmacelera (Spain) and Fluidic Sciences (UK), targeting enabling technologies in healthcare and life sciences with B2B commercialization strategies.
Quantifiable outcome
- Over 30% IRR delivered by HERAN HealthTech Fund I
- +2 more outcomes
Companies that use HERAN Partners
Customer profileNamed customers4 records
Segments1 record
Ideal customer profiles1 record
HERAN Partners technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
HERAN Partners partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered strategic, technology and program.
- SAGES Ingenuity (SINC Fund)strategicInnovation arm of Society of American Gastrointestinal and Endoscopic Surgeons. Strategic investment representing strong validation from global surgical community for HyperVision Surgical's technology.
- Macmillan Cancer SupportstrategicUK's leading cancer charity providing strategic investment and validation for HyperVision Surgical's surgical intelligence technology aimed at improving cancer surgery outcomes.
- imecstrategicWorld's leading independent nanoelectronics R&D hub co-developing HyperVision Surgical's next-generation hyperspectral sensing technology including design, development and manufacturing of new spectral sensor.
- NVIDIAtechnologyNVIDIA IGX architecture powers HyperVision's HYPERSNAP® real-time AI inference in the operating room, providing high-performance edge computing capabilities.
- Innovate UK Investor Partnerships ProgrammeprogramUK government initiative supporting innovative UK companies in attracting investment. HERAN Partners is a selected investor in this program for UK-based companies.
- General InceptionstrategicSilicon Valley company igniter that formed strategic alliance with Pharmacelera in 2023. Pharmacelera serves as GI's AI drug discovery strategic partner. GI's Chief Scientific Officer Venkat Reddy sits on Pharmacelera's Board of Directors. Pharmacelera's technology has strengthened IP for several GI portfolio companies.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
HERAN Partners competitors and assessment
Company assessmentEmerging players
- LUMO Labs: Dutch-based early-stage tech and healthtech venture capital fund. Comparable to HERAN in early-stage healthtech focus and as a co-investor (led the Nuclivision round with HERAN), though broader in sector scope.
Direct peers
- Inkef Capital: Dutch venture capital firm investing across technology and healthcare/life sciences with a pan-European mandate. Comparable to HERAN in early-to-growth stage focus and European healthcare exposure.
- BioGeneration Ventures: Dutch venture capital firm dedicated to early-stage life sciences companies, including therapeutics, medtech and diagnostics. Comparable to HERAN in stage focus (seed/Series A), European footprint, and life sciences specialization.
- Capricorn Partners: Belgian-headquartered independent manager of venture capital and growth funds, including the Capricorn Healthtech Fund. Directly comparable to HERAN as a fellow Belgian healthcare-focused VC and co-investor in deals such as Aspect Analytics.
- Kurma Partners: European venture capital firm focused on healthcare and life sciences, with funds spanning early-stage biotech, medtech and digital health. Directly comparable in sector specialization and European scope.
- Newton Biocapital: Belgium-based venture capital firm focused on early-stage life sciences companies across therapeutics, diagnostics and medical devices. Closely comparable to HERAN as a fellow Belgian specialist life sciences investor at similar fund scale.
- Forbion: Leading European life sciences venture capital firm investing across biotech, medtech and digital health from seed through growth stages. Directly comparable to HERAN given overlapping healthcare/life sciences thesis and pan-European focus, though at materially larger fund sizes.
- Vesalius Biocapital: European specialist life sciences venture capital firm investing in later-stage therapeutics and medical devices. Comparable to HERAN in sector focus and European geographic orientation.
- Andera Partners: European private equity and venture capital firm with a dedicated Life Sciences practice investing across Europe. Comparable to HERAN in healthcare focus and European geographic scope, though with a broader platform.
Broad incumbents
- GIMV: Large Belgian-listed investment company with a long-standing healthcare and life sciences practice. Comparable as a Belgian healthcare investor, but operates as a broader multi-sector platform rather than a dedicated healthcare specialist like HERAN.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
HERAN Partners social profiles
Digital presenceHERAN Partners compliance and trust
Trust signalCompliance1 record
HERAN Partners financial estimates
Financial estimateRevenue estimate
Valuation estimate
HERAN Partners leadership team
Management profileNumber of profiles
Profiles11 records
HERAN Partners funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HERAN Partners M&A and investment
M&A and investmentM&A
Investments10 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HERAN Partners
What does HERAN Partners do?
HERAN Partners is a specialist venture capital firm that invests venture and growth capital in early-stage healthcare, medtech, and life sciences companies across Europe. The firm manages dedicated HealthTech funds that deploy capital at seed, Series A and Series B stages into enabling technologies with strong clinical backbones and B2B commercialization strategies, complemented by mentorship, network access and operational support to portfolio companies.
Is HERAN Partners a public or private company?
HERAN Partners is a private company. It is classified as management employee owned and is currently operating.
When was HERAN Partners founded?
HERAN Partners was founded in 2020. It employs 1 to 10 people.
Where is HERAN Partners based?
HERAN Partners is headquartered in Antwerp, Belgium, in the Europe region.
How does HERAN Partners make money?
One revenue line is on record: venture Capital Fund Management.
Who are HERAN Partners's main competitors?
LUMO Labs is listed as an emerging player. Direct peers are Inkef Capital, BioGeneration Ventures, Capricorn Partners, Kurma Partners, Newton Biocapital, Forbion, Vesalius Biocapital and Andera Partners. GIMV is listed as a broad incumbent.
Does HERAN Partners have an API?
No public API is recorded for HERAN Partners.